Given the presence of the BRAF mutation, the patient was enrolled in a NCCN sponsored randomized controlled trial investigating dabrafenib versus dabrafenib in combination with trametinib in BRAF mutated thyroid cancer (NCT01723202). This evidence concerns the gene BRAF and thyroid cancer.